AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

822.930

+15.2981.89%

Number of Gainers:6

Number of Losers:21

Number of Flat:17

PE:- -

High:823.780

Open:810.347

Low:810.126

Close:807.632

Loading ...

Top 20 Holders and Range of Units for Attaching Options-PIQ.AX

Application for quotation of securities - PIQ-PIQ.AX

OncoSil Medical Completes Patient Recruitment for Pancreatic Cancer Study

MT Newswires Live

Prescient Share Purchase Plan Investor Presentation-PTX.AX

Prescient Therapeutics’ PTX-100 Progresses to Phase 2a Trials after Outstanding Phase 1b Results

ASX ALERT-Completion of Recruitment in PANCOSIL Study-OSL.AX

US Stock Cryptocurrency Concept Stocks Soar, BMNR Up 17.66%

Analysis: Ripple's Application for a Federal Reserve Master Account Is More Significant Than Applying for a Central Bank License

Notification regarding unquoted securities - IMR-IMR.AX

Monash IVF Group Discloses Interim Remuneration Package for Acting CEO

MT Newswires Live

Proteomics Wins US Billing Code for Kidney Function Detection Test

MT Newswires Live

Companies Like Actinogen Medical (ASX:ACW) Are In A Position To Invest In Growth

Simply Wall St.

ASX ALERT-Receipt of second advance for FY25 R&D Tax Incentive-ACR.AX

Application for quotation of securities - ACR-ACR.AX

ASX ALERT-AMA grants reimbursement code for Next-Gen PromarkerD test-PIQ.AX

Acting CEO Remuneration Update-MVF.AX

WSJ: Ripple Is Seeking to Obtain a National Bank Charter

Newland Digital Technology Establishes US Subsidiary, Obtains MSB License

MT Newswires Live

Ceasing to be a substantial holder from MUFG-MYX.AX

Notice under Section 708A-PAR.AX

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":822.92975,"timestamp":1751867999994,"preClose":807.6317,"halted":0,"volume":52263881,"delay":0,"changeRate":0.018942,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":15.298035,"latestTime":"07-07 16:00:00 AEST","open":810.34735,"high":823.78015,"low":810.1261,"amount":145312507,"amplitude":0.016906,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1751932800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1751846400000,1751868000000]],"turnoverRate":0.001564,"increases":7,"decrements":20,"flats":17,"marketCap":129661500662.375,"floatMarketCap":127306754182.9375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":823.78015,"amplitude":0.016906,"preClose":807.6317,"low":810.1261,"latestPrice":822.92975,"volume":52263881,"delay":0,"open":810.34735,"prevYearClose":936.801,"prevWeekClose":807.632,"prevMonthClose":795.022,"prevQuarterClose":795.022,"fiveDayClose":795.022,"twentyDayClose":806.248,"sixtyDayClose":809.644,"secType":"PLATE","market":"AU","turnoverRate":0.001564,"marketCap":129661500662.375,"floatMarketCap":127306754182.9375,"timestamp":1751867999994,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":6,"down":21,"flat":17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548254337","title":"Top 20 Holders and Range of Units for Attaching Options-PIQ.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548254337","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548254337?lang=en_us&edition=fundamental","pubTime":"2025-07-04 10:03","pubTimestamp":1751594628,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250704:nASX8s79jl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250704:nASX2ZfPm0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","BK7508","PIQ.AU"],"gpt_icon":0},{"id":"2548337418","title":"Application for quotation of securities - PIQ-PIQ.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548337418","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548337418?lang=en_us&edition=fundamental","pubTime":"2025-07-04 09:59","pubTimestamp":1751594367,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250704:nASX3vXTCr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250704:nASX1W9vPY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PIQ.AU","BK7048"],"gpt_icon":0},{"id":"2548483339","title":"OncoSil Medical Completes Patient Recruitment for Pancreatic Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2548483339","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548483339?lang=en_us&edition=fundamental","pubTime":"2025-07-04 08:57","pubTimestamp":1751590659,"startTime":"0","endTime":"0","summary":"OncoSil Medical  completed patient recruitment for the Pancosil study in patients with non-progressive locally advanced pancreatic cancer, with a total of 20 patients enrolled in the study, according to a Friday Australian bourse filing.The study is a phase 1/2 feasibility trial initiated by the Amsterdam University Medical Center in the Netherlands, and it is evaluating the safety and feasibility of computed tomography -guided percutaneous radionuclide therapy using the OncoSil device.The device delivers a targeted intratumoural placement of phosphorous-32 in the treatment of locally advanced unresectable pancreatic cancer.The primary objective is to study a novel delivery method for the OncoSil device via a CT-guided percutaneous approach, the filing said. The firm expects preliminary data from the study to be available later this year.The company's shares were down 2% in recent Friday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7048","BK7508","OSL.AU"],"gpt_icon":0},{"id":"2548333302","title":"Prescient Share Purchase Plan Investor Presentation-PTX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548333302","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548333302?lang=en_us&edition=fundamental","pubTime":"2025-07-04 07:19","pubTimestamp":1751584763,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250703:nASX9JZ7D5","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nASX262Mb0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","PTX.AU"],"gpt_icon":0},{"id":"2548332903","title":"Prescient Therapeutics’ PTX-100 Progresses to Phase 2a Trials after Outstanding Phase 1b Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2548332903","media":"Small Caps","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548332903?lang=en_us&edition=fundamental","pubTime":"2025-07-04 07:19","pubTimestamp":1751584756,"startTime":"0","endTime":"0","summary":"Clinical-stage oncology company Prescient Therapeutics  is looking to disrupt a US$1.8 billion market on the back of outstanding Phase 1b clinical trial data for lead candidate PTX-100 to treat cutaneous T-cell lymphoma .Now in its Phase 2a trial, the advanced drug has delivered a 64% tumour halt or shrinkage in patients with the rare but relentless cancer, with only 4% reporting serious adverse effects.This compares to incumbent therapies which have demonstrated a 36% chance of any relief and adverse effects in 98% of patients.Chief executive officer James McDonnell said the trial results give Prescient a shot at becoming one of Australia’s biotech success stories.“PTX-100 has given us highly-encouraging clinical data and we are now looking to advance our clinical program toward registration,” he said.“It is an exciting development which could potentially be applied to 22% of all cancers, so there is a significant opportunity for us to touch millions of lives with this potentially lif","market":"nz","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/07/Prescient-Therapeutics-ASX-PTX-PTX-100-Phase-2a-Trials.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/07/Prescient-Therapeutics-ASX-PTX-PTX-100-Phase-2a-Trials.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/prescient-therapeutics-ptx-100-phase-2a-trials-outstanding-results/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK4007","BK7067","LENZ","PTX.AU","BK7508","BK4539","BK4139"],"gpt_icon":0},{"id":"2548733826","title":"ASX ALERT-Completion of Recruitment in PANCOSIL Study-OSL.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548733826","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548733826?lang=en_us&edition=fundamental","pubTime":"2025-07-04 06:24","pubTimestamp":1751581455,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250703:nASX3kcDKk","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nASX8k7p5w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","BK7508","OSL.AU"],"gpt_icon":0},{"id":"2548800734","title":"US Stock Cryptocurrency Concept Stocks Soar, BMNR Up 17.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548800734","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548800734?lang=en_us&edition=fundamental","pubTime":"2025-07-03 21:54","pubTimestamp":1751550840,"startTime":"0","endTime":"0","summary":"BlockBeats News, July 3rd, US stock market opening, cryptocurrency concept stocks saw a general rise, including:Bitmine Immersion (BMNR) rose by 17.66% to $68.9;Canaan (CAN) rose by 6.95% to $0.692;Circle (CRCL) rose by 6.4% to $189.45;SharpLink Gaming (SBET) rose by 5.02% to $12.61.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/301171","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK4147","BK4526","BK7096","BK4023","BK4595","CAN.AU","CAN","BK4150","BMNR","BK7502","BK4170","BK7508","BK4600"],"gpt_icon":0},{"id":"2548410918","title":"Analysis: Ripple's Application for a Federal Reserve Master Account Is More Significant Than Applying for a Central Bank License","url":"https://stock-news.laohu8.com/highlight/detail?id=2548410918","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548410918?lang=en_us&edition=fundamental","pubTime":"2025-07-03 08:59","pubTimestamp":1751504340,"startTime":"0","endTime":"0","summary":"BlockBeats News, July 3rd, according to cryptocurrency reporter Eleanor Terrett's comments on \"Ripple's Application for National Bank Charter with the Office of the Comptroller of the Currency ,\" \"In addition to this application, Ripple also applied for a Federal Reserve master account through its acquisition of the trust company Standard Custody last year, which is more significant in terms of access than obtaining an OCC license. Hierarchically, a master account is diamond level, a bank charter is platinum level, a trust company is gold level, and a money transmitter license is silver level.\"\"Historically, the Federal Reserve has resisted allowing cryptocurrency companies direct access to the payment system, although critics argue that this could reduce risk. Currently, the Federal Reserve is defending this position in the Custodia Bank lawsuit, which involves the authorization of depository institutions to obtain master account access, and a judgment is expected to be issued at any ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/301017","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["LU0208291251.USD","1OZmain","US2Y.BOND","LU0648001328.SGD","LU1201861165.SGD","BK4211","LU0130518102.USD","SMP","US12M.BOND","BK4559","BK4100","BK4585","CHTR","BK4124","BK4534","LU0130517989.USD","LU0980610538.SGD","US10Y.BOND","US30Y.BOND","US5Y.BOND","XRP.USD.CC","BK7067","NBHC","LU0130102774.USD","LU1201861249.SGD","OCC.AU","LU0175139822.USD","LU0477156953.USD","LU0211331839.USD","LU0477156797.USD","LU0070302665.USD","US7Y.BOND","LU0648000940.SGD","BK4020","LU0130103400.USD","BK4588","US3Y.BOND","US6M.BOND","LU0289960550.SGD","BK7508","OCC","LU0320765489.SGD"],"gpt_icon":0},{"id":"2548844182","title":"Notification regarding unquoted securities - IMR-IMR.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548844182","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548844182?lang=en_us&edition=fundamental","pubTime":"2025-07-03 08:51","pubTimestamp":1751503900,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250703:nASX6nfKgf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nASX176q2y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMR.AU","BK7007","BK7503","BK7508"],"gpt_icon":0},{"id":"2548684996","title":"Monash IVF Group Discloses Interim Remuneration Package for Acting CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2548684996","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548684996?lang=en_us&edition=fundamental","pubTime":"2025-07-03 08:15","pubTimestamp":1751501751,"startTime":"0","endTime":"0","summary":"Monash IVF Group  disclosed the interim remuneration for acting Chief Executive Malik Jainudeen, effective June 12, reflecting the additional responsibilities of his role during the interim period, according to a Thursday filing with the Australian bourse.Interim remuneration includes a fixed annual salary of AU$401,007 plus a AU$228,000 higher duties allowance, along with eligibility for a short-term incentive of up to 50% of total remuneration and a long-term incentive of up to 60% of base salary, both contingent on performance criteria, the filing said.The appointment has no fixed term, includes a three-month notice, and will revert to Jainudeen's original remuneration terms after the interim period, the filing added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK7113","LU1670710588.SGD","BK7508","LU1670711123.USD","LU1670710661.SGD","MVF.AU","BK4082","BK4504","BK4588","LU1670711040.USD","VFC","BK4202","IVF"],"gpt_icon":0},{"id":"2548644849","title":"Proteomics Wins US Billing Code for Kidney Function Detection Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2548644849","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548644849?lang=en_us&edition=fundamental","pubTime":"2025-07-03 08:13","pubTimestamp":1751501622,"startTime":"0","endTime":"0","summary":"Proteomics International Laboratories  received a dedicated billing code from the American Medical Association for its PromarkerD diagnostic test, which identifies kidney function decline in patients with Type 2 diabetes, according to a Thursday filing with the Australian bourse.The new code will take effect for insurance claims from Oct. 1, the filing said.The company also submitted a pricing recommendation for the test to the Centers for Medicare and Medicaid Services , the filing added.Preliminary pricing for the test is expected in September following a review by CMS's advisory panel, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMS","BK7048","LU1894683348.USD","LU2500361329.USD","LU0738911758.USD","BK4588","LU1003077747.HKD","BK4208","BK4585","LU0949170772.SGD","LU1894683264.USD","PIQ.AU","LU0545039389.USD","LU0553294199.USD","LU0661504455.SGD","LU2637428348.USD","BK7508","LU2346227817.USD"],"gpt_icon":0},{"id":"2548829822","title":"Companies Like Actinogen Medical (ASX:ACW) Are In A Position To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2548829822","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548829822?lang=en_us&edition=fundamental","pubTime":"2025-07-03 07:32","pubTimestamp":1751499142,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/companies-like-actinogen-medical-asxacw-are-in-a-position-to","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ACW.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2548846120","title":"ASX ALERT-Receipt of second advance for FY25 R&D Tax Incentive-ACR.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548846120","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548846120?lang=en_us&edition=fundamental","pubTime":"2025-07-03 07:29","pubTimestamp":1751498952,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250702:nASX5PCg9l","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nASX6bSjP3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2548684661","title":"Application for quotation of securities - ACR-ACR.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548684661","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548684661?lang=en_us&edition=fundamental","pubTime":"2025-07-03 07:23","pubTimestamp":1751498615,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250702:nASX7DMzbn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nASX2z72Tb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ACR.AU","BK7508"],"gpt_icon":0},{"id":"2548845875","title":"ASX ALERT-AMA grants reimbursement code for Next-Gen PromarkerD test-PIQ.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548845875","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548845875?lang=en_us&edition=fundamental","pubTime":"2025-07-03 06:20","pubTimestamp":1751494855,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250702:nASX9H9zc7","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nASX7k8wsV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","PIQ.AU","BK7048"],"gpt_icon":0},{"id":"2548845823","title":"Acting CEO Remuneration Update-MVF.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548845823","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548845823?lang=en_us&edition=fundamental","pubTime":"2025-07-03 06:20","pubTimestamp":1751494830,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250702:nASX4kg81g","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nASX6ZqDgF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7113","MVF.AU","BK7508"],"gpt_icon":0},{"id":"2548175811","title":"WSJ: Ripple Is Seeking to Obtain a National Bank Charter","url":"https://stock-news.laohu8.com/highlight/detail?id=2548175811","media":"Blockbeats","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548175811?lang=en_us&edition=fundamental","pubTime":"2025-07-03 00:42","pubTimestamp":1751474520,"startTime":"0","endTime":"0","summary":"BlockBeats News, July 3rd, according to The Wall Street Journal, Ripple submitted an application for a national bank charter to the Office of the Comptroller of the Currency  on Wednesday, joining the growing number of cryptocurrency companies seeking to enter the mainstream financial system. Its stablecoin, RLUSD, is currently regulated by the New York State Department of Financial Services. If granted a national bank charter, this stablecoin will fall under OCC's oversight. The company stated that it plans to explore offering more cryptocurrency services in the future through this bank charter.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/300995","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["IE00B64PRP62.GBP","LU1883839398.USD","IE00BGHQF748.EUR","STT","BK4020","BK7508","IE0034235188.USD","LU0061475181.USD","OCC.AU","BK4588","LU1894683264.USD","LU1894683348.USD","IE00B3QW5Z07.USD","BK4135","OCC","XRP.USD.CC","BK7067","BK4585"],"gpt_icon":1},{"id":"2548057860","title":"Newland Digital Technology Establishes US Subsidiary, Obtains MSB License","url":"https://stock-news.laohu8.com/highlight/detail?id=2548057860","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548057860?lang=en_us&edition=fundamental","pubTime":"2025-07-02 17:43","pubTimestamp":1751449432,"startTime":"0","endTime":"0","summary":"Newland Digital Technology  established a wholly-owned US subsidiary named NovaPay.The move aims to enhance cross-border payment infrastructure, integrate resources and strengthen overseas regulatory compliance, according to a Wednesday filing with the Shenzhen bourse.NovaPay has obtained a money services business  license from the Financial Crimes Enforcement Network.Shares of the digital payments company closed 1% higher Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0067","000997","BK0028","BK0091","BK0188","BK7501","MSB","BK0068","BK0166","MSB.AU","BK7508","BK4006","BK0170","BK0231","BK0185","BK0196","BK0077","BK7067"],"gpt_icon":0},{"id":"2548866253","title":"Ceasing to be a substantial holder from MUFG-MYX.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548866253","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548866253?lang=en_us&edition=fundamental","pubTime":"2025-07-02 15:54","pubTimestamp":1751442843,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250702:nASX1y17DF","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nASX1yYf34:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MYX.AU","BK7096"],"gpt_icon":0},{"id":"2548853077","title":"Notice under Section 708A-PAR.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548853077","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548853077?lang=en_us&edition=fundamental","pubTime":"2025-07-02 10:59","pubTimestamp":1751425198,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250702:nASX6vYpKD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nASX6p40W5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAR.AU","BK7508","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":2,"totalSize":152,"code":"91000000","status":"200"}]}}